

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Single Technology Appraisal

Bimekizumab for treating active non-radiographic axial spondyloarthritis ID4010

Provisional Stakeholder List

Consultees	Commentators (no right to submit or appeal)
<p><u>Company</u></p> <ul style="list-style-type: none"> • UCB Pharma (bimekizumab) <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> • Action on Pain • Arthritis Action • Arthritis and Musculoskeletal Alliance • Back Care • Brain and Spine Foundation • National Axial Spondyloarthritis Society • Pain Concern • Pain UK • South Asian Health Foundation • Specialised Healthcare Alliance • Versus Arthritis <p><u>Healthcare professional groups</u></p> <ul style="list-style-type: none"> • British Geriatrics Society • British Institute of Musculoskeletal Medicine • British Myology Society • British Orthopaedic Association • British Pain Society • British Society for Paediatric and Adolescent Rheumatology • British Society for Rheumatology • British Society of Rehabilitation Medicine • Chartered Society of Physiotherapy • Physiotherapy Pain Association • Primary Care Rheumatology & Musculoskeletal Medicine Society • Royal College of General Practitioners • Royal College of Nursing 	<p><u>General</u></p> <ul style="list-style-type: none"> • All Wales Therapeutics and Toxicology Centre • Allied Health Professionals Federation • Board of Community Health Councils in Wales • British National Formulary • Care Quality Commission • Department of Health, Social Services and Public Safety for Northern Ireland • Healthcare Improvement Scotland • Medicines and Healthcare products Regulatory Agency • National Association of Primary Care • National Pharmacy Association • NHS Confederation • Scottish Medicines Consortium • Welsh Government • Welsh Health Specialised Services Committee <p><u>Possible comparator companies</u></p> <ul style="list-style-type: none"> • AbbVie (adalimumab, upadacitinib) • Amgen (adalimumab) • Biogen Biosimilars (adalimumab, etanercept) • Celltrion Healthcare (adalimumab) • Eli Lilly (ixekizumab) • Fresenius Kabi (adalimumab) • Merck Sharp & Dohme (golimumab) • Novartis (secukinumab) • Pfizer (etanercept) • Sandoz (adalimumab, etanercept)

Provisional stakeholder list for the evaluation of bimekizumab for treating active non-radiographic axial spondyloarthritis ID4010

Issue date: November 2022

© National Institute for Health and Care Excellence 2022. All rights reserved.

Page 1 of 3

Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> • Royal College of Occupational Therapists • Royal College of Pathologists • Royal College of Physicians • Royal Pharmaceutical Society • Royal Society of Medicine • Society for Endocrinology • UK Clinical Pharmacy Association <p><u>Others</u></p> <ul style="list-style-type: none"> • Department of Health and Social Care • NHS England 	<ul style="list-style-type: none"> • UCB Pharma (certolizumab pegol) <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> • Bone Research Society • Chronic Pain Policy Coalition • Cochrane Musculoskeletal Group • Cochrane UK • Genomics England • MRC Clinical Trials Unit • National Institute for Health Research • Orthopaedic Research UK • Pain Relief Foundation • Society for Back Pain Research <p><u>Associated Public Health groups</u></p> <ul style="list-style-type: none"> • Public Health Wales • UK Health Security Agency

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

Definitions:

Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement¹, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

¹ Non company consultees are invited to submit statements relevant to the group they are representing.

Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance, and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.